EP0994717A4 - Treatment of autoimmune disease using tolerization in combination with methotrexate - Google Patents
Treatment of autoimmune disease using tolerization in combination with methotrexateInfo
- Publication number
- EP0994717A4 EP0994717A4 EP98908452A EP98908452A EP0994717A4 EP 0994717 A4 EP0994717 A4 EP 0994717A4 EP 98908452 A EP98908452 A EP 98908452A EP 98908452 A EP98908452 A EP 98908452A EP 0994717 A4 EP0994717 A4 EP 0994717A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- tolerization
- methotrexate
- treatment
- combination
- autoimmune disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B41—PRINTING; LINING MACHINES; TYPEWRITERS; STAMPS
- B41J—TYPEWRITERS; SELECTIVE PRINTING MECHANISMS, i.e. MECHANISMS PRINTING OTHERWISE THAN FROM A FORME; CORRECTION OF TYPOGRAPHICAL ERRORS
- B41J2/00—Typewriters or selective printing mechanisms characterised by the printing or marking process for which they are designed
- B41J2/005—Typewriters or selective printing mechanisms characterised by the printing or marking process for which they are designed characterised by bringing liquid or particles selectively into contact with a printing material
- B41J2/01—Ink jet
- B41J2/21—Ink jet for multi-colour printing
- B41J2/2107—Ink jet for multi-colour printing characterised by the ink properties
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/542—Mucosal route oral/gastrointestinal
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING OR COUNTING
- G06K—GRAPHICAL DATA READING; PRESENTATION OF DATA; RECORD CARRIERS; HANDLING RECORD CARRIERS
- G06K2215/00—Arrangements for producing a permanent visual presentation of the output data
- G06K2215/0082—Architecture adapted for a particular function
- G06K2215/0094—Colour printing
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING OR COUNTING
- G06K—GRAPHICAL DATA READING; PRESENTATION OF DATA; RECORD CARRIERS; HANDLING RECORD CARRIERS
- G06K2215/00—Arrangements for producing a permanent visual presentation of the output data
- G06K2215/0082—Architecture adapted for a particular function
- G06K2215/0097—Printing on special media, e.g. labels, envelopes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Ophthalmology & Optometry (AREA)
- Biomedical Technology (AREA)
- Physical Education & Sports Medicine (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US3672297P | 1997-01-24 | 1997-01-24 | |
US36722P | 1997-01-24 | ||
PCT/US1998/001648 WO1998032451A1 (en) | 1997-01-24 | 1998-01-26 | Treatment of autoimmune disease using tolerization in combination with methotrexate |
Publications (2)
Publication Number | Publication Date |
---|---|
EP0994717A1 EP0994717A1 (en) | 2000-04-26 |
EP0994717A4 true EP0994717A4 (en) | 2000-07-26 |
Family
ID=21890248
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP98908452A Withdrawn EP0994717A4 (en) | 1997-01-24 | 1998-01-26 | Treatment of autoimmune disease using tolerization in combination with methotrexate |
Country Status (10)
Country | Link |
---|---|
EP (1) | EP0994717A4 (en) |
JP (1) | JP2001511134A (en) |
KR (1) | KR20000070460A (en) |
AU (1) | AU6648898A (en) |
BR (1) | BR9807112A (en) |
CA (1) | CA2278152A1 (en) |
HU (1) | HUP0001960A2 (en) |
IL (1) | IL131025A0 (en) |
NO (1) | NO993600L (en) |
WO (1) | WO1998032451A1 (en) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20040103930A (en) | 2002-02-11 | 2004-12-09 | 앤태어스 파머, 인코퍼레이티드 | Intradermal injector |
ES2716135T5 (en) | 2005-01-24 | 2023-06-15 | Antares Pharma Inc | Needle-assisted jet injector with pre-filled syringe |
GB0523576D0 (en) * | 2005-11-18 | 2005-12-28 | Theradeas Ltd | Drug composition and its use in therapy |
US8251947B2 (en) | 2006-05-03 | 2012-08-28 | Antares Pharma, Inc. | Two-stage reconstituting injector |
WO2007131025A1 (en) | 2006-05-03 | 2007-11-15 | Antares Pharma, Inc. | Injector with adjustable dosing |
US8814834B2 (en) | 2008-03-10 | 2014-08-26 | Antares Pharma, Inc. | Injector safety device |
ES2738539T3 (en) | 2008-08-05 | 2020-01-23 | Antares Pharma Inc | Multi dose injector |
JP5732039B2 (en) | 2009-03-20 | 2015-06-10 | アンタレス・ファーマ・インコーポレーテッド | Hazardous drug injection system |
US9044479B2 (en) | 2010-06-16 | 2015-06-02 | Bruce Chandler May | Use of levocetirizine and montelukast in the treatment of influenza, common cold and inflammation |
US8496619B2 (en) | 2011-07-15 | 2013-07-30 | Antares Pharma, Inc. | Injection device with cammed ram assembly |
US9220660B2 (en) | 2011-07-15 | 2015-12-29 | Antares Pharma, Inc. | Liquid-transfer adapter beveled spike |
PT2822618T (en) | 2012-03-06 | 2024-03-04 | Antares Pharma Inc | Prefilled syringe with breakaway force feature |
JP6457383B2 (en) | 2012-04-06 | 2019-01-23 | アンタレス・ファーマ・インコーポレーテッド | Needle-assisted jet injection of testosterone composition |
WO2013169800A1 (en) | 2012-05-07 | 2013-11-14 | Antares Pharma, Inc. | Injection device with cammed ram assembly |
EP4349383A3 (en) | 2013-02-11 | 2024-06-19 | Antares Pharma, Inc. | Needle assisted jet injection device having reduced trigger force |
CA2905031C (en) | 2013-03-11 | 2018-01-23 | Hans PFLAUMER | Dosage injector with pinion system |
WO2014165136A1 (en) | 2013-03-12 | 2014-10-09 | Antares Pharma, Inc. | Constant volume prefilled syringes and kits thereof |
EP3300734B1 (en) | 2013-03-13 | 2019-08-14 | Inflammatory Response Research, Inc. | Use of levocetirizine and montelukast in the treatment of autoimmune disorders |
JP2016512262A (en) | 2013-03-13 | 2016-04-25 | インフラマトリー・レスポンス・リサーチ・インコーポレイテッド | Use of levocetirizine and montelukast in the treatment of vasculitis |
ES2770760T3 (en) | 2013-03-13 | 2020-07-03 | Inflammatory Response Res Inc | Use of levocetirizine and montelukast in the treatment of traumatic injuries |
JP2017526728A (en) | 2014-09-15 | 2017-09-14 | インフラマトリー・レスポンス・リサーチ・インコーポレイテッド | Levocetirizine and montelukast in the treatment of inflammation-mediated conditions |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1992004049A1 (en) * | 1990-09-06 | 1992-03-19 | Rijksuniversiteit Te Utrecht | Inhibitor of lymphocyte response and immune-related disease |
WO1993016724A1 (en) * | 1992-02-28 | 1993-09-02 | Autoimmune, Inc. | Bystander suppression of autoimmune diseases |
EP0666080A1 (en) * | 1987-06-24 | 1995-08-09 | Brigham & Women's Hospital | Treatment of autoimmune diseases by oral administration of autoantigens |
WO1996040235A1 (en) * | 1995-06-07 | 1996-12-19 | Nexstar Pharmaceuticals, Inc. | Method to use superantigens to target subpopulations of t cells |
WO1996041644A1 (en) * | 1995-06-13 | 1996-12-27 | Nippon Meat Packers, Inc. | Oral remedy for rheumatoid arthritis and functional food |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5571499A (en) * | 1987-06-24 | 1996-11-05 | Autoimmune, Inc. | Treatment of autoimmune diseases by aerosol administration of autoantigens |
US5571500A (en) * | 1987-06-24 | 1996-11-05 | Autoimmune, Inc. | Treatment of autoimmune diseases through administration by inhalation of autoantigens |
-
1998
- 1998-01-26 EP EP98908452A patent/EP0994717A4/en not_active Withdrawn
- 1998-01-26 AU AU66488/98A patent/AU6648898A/en not_active Abandoned
- 1998-01-26 IL IL13102598A patent/IL131025A0/en unknown
- 1998-01-26 BR BR9807112-2A patent/BR9807112A/en not_active Application Discontinuation
- 1998-01-26 CA CA002278152A patent/CA2278152A1/en not_active Abandoned
- 1998-01-26 HU HU0001960A patent/HUP0001960A2/en unknown
- 1998-01-26 KR KR1019997006698A patent/KR20000070460A/en not_active Application Discontinuation
- 1998-01-26 WO PCT/US1998/001648 patent/WO1998032451A1/en not_active Application Discontinuation
- 1998-01-26 JP JP53225298A patent/JP2001511134A/en active Pending
-
1999
- 1999-07-23 NO NO993600A patent/NO993600L/en unknown
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0666080A1 (en) * | 1987-06-24 | 1995-08-09 | Brigham & Women's Hospital | Treatment of autoimmune diseases by oral administration of autoantigens |
WO1992004049A1 (en) * | 1990-09-06 | 1992-03-19 | Rijksuniversiteit Te Utrecht | Inhibitor of lymphocyte response and immune-related disease |
WO1993016724A1 (en) * | 1992-02-28 | 1993-09-02 | Autoimmune, Inc. | Bystander suppression of autoimmune diseases |
WO1996040235A1 (en) * | 1995-06-07 | 1996-12-19 | Nexstar Pharmaceuticals, Inc. | Method to use superantigens to target subpopulations of t cells |
WO1996041644A1 (en) * | 1995-06-13 | 1996-12-27 | Nippon Meat Packers, Inc. | Oral remedy for rheumatoid arthritis and functional food |
Non-Patent Citations (2)
Title |
---|
AL-SABBAGH, A.M., ET AL.: "Combination of oral antigens with oral methotrexate enhances suppression of autoimmune disease", JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, vol. 99, no. 1(PART 2), Abs. 99, January 1997 (1997-01-01), pages s24, XP000909440 * |
See also references of WO9832451A1 * |
Also Published As
Publication number | Publication date |
---|---|
BR9807112A (en) | 2001-09-18 |
HUP0001960A2 (en) | 2000-10-28 |
AU6648898A (en) | 1998-08-18 |
KR20000070460A (en) | 2000-11-25 |
WO1998032451A1 (en) | 1998-07-30 |
JP2001511134A (en) | 2001-08-07 |
IL131025A0 (en) | 2001-01-28 |
EP0994717A1 (en) | 2000-04-26 |
NO993600L (en) | 1999-09-23 |
NO993600D0 (en) | 1999-07-23 |
CA2278152A1 (en) | 1998-07-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL131025A0 (en) | Treatment of autoimmune disease using tolerization in combination with methotrexate | |
ZA989461B (en) | Methods and compositions for the treatment of autoimmune disease using heat shock proteins | |
ZA9710339B (en) | Xanthines and their therapeutic use | |
ZA983452B (en) | Substituted pyrrolopyridines useful in the treatment of inflammatory diseases. | |
EP0924983A4 (en) | S(-)-tolterodine in the treatment of urinary and gastrointestinal disorders | |
EP0966386A4 (en) | Human powered vehicle | |
IL139589A0 (en) | Use of cyclosporins in the treatment of inflammatory autoimmune diseases | |
HUP0001276A3 (en) | Illuminating body for swimming pools and similar | |
IL133088A0 (en) | Novel triptolide derivatives useful in the treatment of autoimmune diseases | |
HU9602750D0 (en) | Treatment of autoimmune disease using oral tolerization and/or type i interferon | |
HU9602751D0 (en) | Treatment of autoimmune disease using oral tolerization and/or th2-enhancing cytokines | |
HUP9900147A3 (en) | Therapeutic agents and autoimmune diseases | |
GB9419553D0 (en) | Polypeptides and their use in the treatment of auto-immune disease | |
HK1025954A1 (en) | Triptolide derivatives useful in the treatment of autoimmune diseases | |
EP0797440A4 (en) | The treatment of autoimmune disease using 2-amino purine derivatives | |
AU2976597A (en) | Autoimmune disease therapeutic agent | |
GB9621825D0 (en) | Microparticles and their use as therapeutic vehicles | |
IL129460A0 (en) | Use of lofexidine in the treatment of behavioral disorders | |
EP1073459A4 (en) | Compositions and methods for tolerization in immune complex-mediated disease progression | |
HUP9902802A3 (en) | Pyridyl- and pyrimidyl-piperazines in the treatment of substance abuse disorders | |
AU7262800A (en) | Diagnostic and therapeutic methods in autoimmune disease | |
EP1020517A4 (en) | Gene originating in human chondrocyte | |
IL132845A0 (en) | Non-myeloablative tolerogenic treatment | |
SI0983275T1 (en) | Novel triptolide derivatives useful in the treatment of autoimmune diseases | |
TW345130U (en) | Improved structure for warming cup used in vehicle |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 19990818 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20000614 |
|
AK | Designated contracting states |
Kind code of ref document: A4 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE |
|
RIC1 | Information provided on ipc code assigned before grant |
Free format text: 7A 61K 31/505 A, 7A 61K 39/00 B, 7A 61P 37/00 B, 7A 61K 39/00 J, 7A 61K 31:505 J |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20000801 |